Structural insight into KRAS conformational cycling exposed temporary binding opportunities, overturning the “undruggable” paradigm and enabling inhibitors that engage previously hidden pockets.

New clinical trial data show KRAS-blocking drugs may significantly improve survival for the disease. “I think this is truly an earth-shattering moment in pancreatic cancer.” Daraxonrasib, an ...

SAN DIEGO -- Treatment with investigational elisrasib, a next-generation KRAS G12C inhibitor, showed efficacy in patients with advanced non-small cell lung cancer (NSCLC) with and without previous ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

SAN DIEGO -- Investigational zoldonrasib was well tolerated and showed encouraging clinical activity in previously treated KRAS G12D-mutated non-small cell lung cancer (NSCLC), according to a phase I ...

Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You ...

KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT ...

A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene mutation behaves differently from other variants. The study, published in Cancer ...

Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials. AstraZeneca has found another potential gold nugget in ...

Mutations in KRAS drive PDAC. (A) Illustration depicting different stages of PDAC, in which tumors originating in the pancreas (stage 1) first extend to lymph nodes and bile ducts (stage 2), then ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to a KRAS G12D inhibitor that is on the cusp of the clinic. Kumquat, which ...